Tsunoda Akira, Nakao Kentaro, Kamiyama Goichi, Narita Kazuhiro, Yamazaki Katsuo, Watanabe Makoto, Suzuki Naoto, Oonaka Tooru, Kusano Mitsuo
Dept. of General and Gastroenterological Surgery, Showa University School of Medicine, Tokyo, Japan.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:135-7.
Various kinds of combination chemotherapies with 5-FU as a base agent have been performed for patients with advanced or recurrent colorectal cancer. S-1 was a newly developed 5-FU derivative and was orally administered. One of the combination therapies with S-1 plus irinotecan (CPT-11) has also been expected to have a better therapeutic value. Recently this combination therapy has been undertaken by our department, and its clinical use and toxicities are described in this article.
对于晚期或复发性结直肠癌患者，已经开展了以5-氟尿嘧啶（5-FU）为基础药物的各种联合化疗。S-1是一种新开发的5-FU衍生物，通过口服给药。S-1联合伊立替康（CPT-11）的联合治疗方案之一也被认为具有更好的治疗价值。最近，我们科室开展了这种联合治疗，本文将描述其临床应用及毒性。
